Regardless of the necessity for sufferers with myeloproliferative neoplasms (MPNs) to take part in medical trials, challenges persist associated to the geographically dispersed...
Amongst sufferers with relapsed or refractory follicular lymphoma (FL), the therapy mixture of Monjuvi (tafasitamab-cxix) plus Revlimid (lenalidomide) and Rituxan (rituximab) has been...
